General paperPhospholipid regulation of a cyclic AMP-specific phosphodiesterase (PDE4) from U937 cells
References (26)
Biochem. Pharmacol.
(1992)- et al.
J. Allergy Clin. Immunol.
(1982) - et al.
J. Allergy Clin. Immunol.
(1987) J. Biol. Chem.
(1990)Adv. Can. Res.
(1991)- et al.
Biochem. Biophys. Res. Commun.
(1993) - et al.
Arch. Biochem. Biophys.
(1983) - et al.
Arch. Biochem. Biophys.
(1976) - et al.
J. Biol. Chem.
(1994) - et al.
Biochem. Biophys. Res. Commun.
(1990)
Eur. J. Pharmacol.
(1995)
J. Biol. Chem.
(1992)
Mol. Pharmacol.
(1994)
Cited by (10)
2,1,3-Benzothiadiazine derivatives: Synthesis and screening versus PDE4 enzyme
2005, FarmacoCitation Excerpt :Chemical, physical and spectroscopic data of already known intermediates (30, 32–39, 41 and 44) [24,38–41] and final compounds (3, 4, 7, 9, 10, 12, 24, 25, 27 and 29) [24,26,42,43] are in agreement with those reported in literature. All compounds were tested at 100 μM concentration for their ability to inhibit the activity of PDE4 extracted from U937 cellular line [44–46]. Also the BTDs previously showing activity on human recombinant enzyme PDE4D3 from Baculovirus/Sf21 insect cell system (3, 4 and 7) [24] and others related compounds (9, 10, 12, 24, 25, 27 and 29) previously synthesized and characterized by antiviral properties [26,42,43], were tested using rolipram as reference compound (Table 1).
The Role of Phosphodiesterase Enzymes in Allergy and Asthma
1998, Advances in PharmacologyCyclic AMP specific phosphodiesterase activity and colon cancer cell motility
2000, Clinical and Experimental Metastasis
Copyright © 1995 Published by Elsevier Inc.